Treats serious infections due to susceptible strains of streptococci, pneumococci, and…. ANDA 212770, held by Quagen. Lincomycin Hydrochloride.
As of Nov 15, 2026, ANDA 212770 (Lincomycin Hydrochloride), held by Quagen, was first approved by FDA on Mar 12, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING, before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 12, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lincomycin HydrochlorideEQ 300MG BASE/ML · injectable;injection | Lincomycin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
